Speaker: Sebastian Stintzing

0:00:38

What’s next for patients with BRAF VJ600E mutant metastatic CRC?

0:02:11

FIRE-4: evaluation of 1L efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC

0:02:28

The evolving treatment paradigm for BRAF V600E-mutant mCRC

0:01:24

FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab as 1L treatment of BRAF V600E-mutant mCRC

0:02:06

Baseline analysis of patients enrolled in the BERING CRC study

0:01:49

FIRE-6: avelumab + FOLFIRI plus cetuximab followed by avelumab maintenance in untreated RASwt mCRC

0:00:44

Implications of the post-hoc Q-TWiST analysis of fruquintinib in refractory mCRC

0:03:08

Targeting less common mutations in colorectal cancer

0:00:52

Baseline liquid biopsy in combination with tissue biopsy to detect RAS mutations in mCRC

0:01:31

Baseline characteristics of patients enrolled in the BERING CRC study

0:00:42

Importance of gaining real-world data following approvals of therapies

0:00:44

ASCO GI highlights: preventing early-onset GI cancer

0:02:11

Colorectal cancer trial updates at ASCO 2021

0:04:25

FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRC

0:03:07

FIRE-4: influence of baseline liquid biopsy results in 1L efficacy of FOLFIRI/cetux in RAS-WT mCRC

0:02:05

Fruquintinib vs. placebo in mCRC: Q-TWiST analysis from FRESCO-2

0:02:11

Temsirolimus with BERT for the treatment of relapsed mantle cell and follicular lymphoma

0:01:55

Combination immunotherapy in gastrointestinal cancers: highlights from ASCO 2017

0:03:55

The molecular mechanisms of epigenetic therapies: LTRs and TINATs

0:16:55

Mutational Profiling in Patients with MDS: Ready for every-day use in the clinic?

0:09:18

iwNHL 2015 roundtable: Using B-cell biology to inform therapy

0:03:53

GvHD biology: tissue tolerance, the micriobiome & biomarkers

1:24:05

Colorectal Cancer in 2015 Webinar | Fight Colorectal Cancer

0:03:30

Key priorities in transplant research